Healthcare / Medical Instruments & SuppliesUpdated 2026-05-10 22:07 UTC

BME/PRM stock hub

BME/PRM has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BME/PRMis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

224.6M

Madrid Stock Exchange

Market data

Price

Recent price action with selectable time range.

BME/PRMBME/PRM

—

Loading chart…

In the news

Latest news · BME/PRM

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E11.4

P25 n/aP50 n/aP75 n/a

Trailing P/E13.5

P25 n/aP50 n/aP75 n/a

ROE12.5

P25 n/aP50 n/aP75 n/a

ROIC12.2

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BME/PRM market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

243

Groups with data

Currency

EUR

Showing 243 of 243 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Spain
Country code	ES
Employees	984
Employees Change	26%
Employees Change Percent	2.71
Enterprise value	EUR 217M
Exchange	Madrid Stock Exchange
Financial currency	EUR
First seen	2026-05-10
Industry	Medical Instruments & Supplies
Isin	ES0170884417
Last refreshed	2026-05-10
Market cap	EUR 224.6M
Price	EUR 13
Price currency	EUR
Rev Per Employee	255,989.86x
Sector	Healthcare
Sic	5047
Symbol	bme/PRM
Website	https://www.prim.es

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	7.43%
EV Earnings	13.01x
EV/EBIT	10.43x
EV/EBITDA	7.14x
EV/FCF	11.96x
EV/Sales	0.86x
FCF yield	8.08%
Forward P/E	11.41x
P/B ratio	1.63x
P/E ratio	13.47x
P/S ratio	0.89x
PE Ratio10 Y	16.11x
PE Ratio3 Y	14.23x
PE Ratio5 Y	14.6x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	8.26%
EBITDA Margin	11.18%
FCF margin	7.2%
Gross margin	49.96%
Gross Profit	EUR 125.9M
Gross Profit Growth	6.67%
Gross Profit Growth Q	14.91%
Gross Profit Growth3 Y	4.9%
Gross Profit Growth5 Y	5.14%
Net Income	EUR 16.7M
Net Income Growth	52.77%
Net Income Growth Q	51.31%
Net Income Growth Quarters	2%
Net Income Growth Years	1%
Net Income Growth3 Y	13.45%
Net Income Growth5 Y	11.33%
Pretax Margin	8.66%
Profit Margin	6.62%
Profit Per Employee	EUR 16,955
Profitable Years	22
ROA	6.73
Roa5y	4.79
ROCE	13.92
ROE	12.52
Roe5y	10.66
ROIC	12.24
Roic5y	8.91

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	7.35%
Cagr15y	9.51%
Cagr1y	26.02%
Cagr20y	3.84%
Cagr3y	11.31%
Cagr5y	7.87%
Div CAGR10	-0.77%
Div CAGR3	7.09%
Div CAGR5	8.18%
EPS Growth	53.13
EPS Growth Q	53.87
EPS Growth Quarters	2
EPS Growth Years	1
EPS Growth3 Y	13.58
EPS Growth5 Y	11.4
FCF Growth	68.58%
FCF Growth Q	-30.05%
FCF Growth5 Y	22.86%
OCF Growth	38.13%
OCF Growth Q	-21.73%
OCF Growth10 Y	2%
OCF Growth5 Y	9.55%
Revenue Growth	7.94x
Revenue Growth Q	9.87x
Revenue Growth Quarters	2x
Revenue Growth Years	5x
Revenue Growth3 Y	3.44x
Revenue Growth5 Y	3.99x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 1.3
Assets	EUR 196.5M
Cash	EUR 23M
Current Assets	EUR 140.9M
Current Liabilities	EUR 47.1M
Debt	EUR 15.5M
Debt EBITDA	EUR 0.51
Debt Equity	EUR 0.11
Debt FCF	EUR 0.85
Equity	EUR 137.6M
Interest Coverage	38.71
Liabilities	EUR 58.9M
Long Term Assets	EUR 55.7M
Long Term Liabilities	EUR 11.8M
Net Cash	EUR 7.6M
Net Cash By Market Cap	EUR 3.37
Net Debt EBITDA	EUR -0.27
Net Debt Equity	EUR -0.05
Net Debt FCF	EUR -0.42
Tangible Book Value	EUR 114.5M
Tangible Book Value Per Share	EUR 6.73
WACC	6.83

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.99
Inventory Turnover	1.83
Net Working Capital	EUR 79.1M
Quick ratio	1.56
Working Capital	EUR 93.8M
Working Capital Turnover	EUR 2.81

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.02%
Dividend Growth	9.42%
Dividend Growth Years	2%
Dividend per share	EUR 0.47
Dividend Years	30
Dividend Yield	3.55%
Ex Div Date	2026-03-10
Last Dividend	EUR 0.11
Payout Frequency	Semi-Annual
Payout Ratio	47.86%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	103.12%
1Y total return	26%
200-day SMA	13.05
3Y total return	37.91%
50-day SMA	13.02
50-day SMA vs 200-day SMA	50under200
5Y total return	46.04%
All Time High	15.75
All Time High Change	-17.46%
All Time High Date	2022-04-01
All Time Low	0.65
All Time Low Change	1,908.96%
All Time Low Date	1996-05-31
ATR	0.3
Beta	0.52
Beta1y	0.23
Beta2y	0.35
Ch YTD	-1.52
High	13.2
High52	13.95
High52 Date	2025-10-30
High52ch	-6.81%
Low	13
Low52	10.65
Low52 Date	2025-06-03
Low52ch	22.07%
Ma50ch	-0.16%
Price vs 200-day SMA	-0.36%
RSI	52.83
RSI Monthly	59.84
RSI Weekly	53.72
Sharpe ratio	0.78x
Sortino ratio	1.46
Total Return	3.54%
Tr YTD	-0.7
Tr15y	290.52%
Tr1m	0.39%
Tr1w	-1.52%
Tr3m	0.83%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 20.8M
Operating Income Growth	15.45
Operating Income Growth Q	45.46
Operating Income Growth3 Y	16.54
Operating Income Growth5 Y	18.95
Operating margin	8.26

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	10,209,068%
Net Borrowing	-2,928,401
Shares Institutions	12.84%
Shares Out	17,013,697
Shares Qo Q	0.03%
Shares Yo Y	0.02%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 18.1M
Average Volume	2,959.6x
Bv Per Share	8.09
CAPEX	EUR -12.3M
Ch10y	47.06
Ch15y	140.3
Ch1m	0.39
Ch1w	-1.52
Ch1y	22.07
Ch20y	20.46
Ch3y	25.6
Ch5y	26.21
Ch6m	-3.35
Change	-1.52%
Change From Open	-1.52
Close	13.2
Days Gap	0
Depreciation Amortization	7,353,490
Dollar Volume	3,510
Earnings Date	2026-09-09
EBIT	EUR 20.8M
EBITDA	EUR 28.2M
EPS	EUR 0.98
F Score	8
FCF	EUR 18.1M
FCF EV Yield	8.36x
FCF Per Share	EUR 1.07
Financing CF	-11,622,529
Fiscal Year End	December
Founded	1,870
Goodwill	11,462,652
Graham Number	13.3561
Graham Upside	2.74
Income Tax	EUR 5.1M
Investing CF	-10,072,704
Is Primary Listing	1
Last Earnings Date	2026-02-27
Last Report Date	2025-12-31
Last Split Date	2008-10-16
Last Split Type	Forward
Lynch Fair Value	EUR 11.1
Lynch Upside	-14.61
Ma150	13.22
Ma150ch	-1.66%
Ma20	13.2
Ma20ch	-1.52%
Net CF	8,654,586
Next Earnings Date	2026-09-09
Open	13.2
P FCF Ratio	12.38
P OCF Ratio	7.37
Payment Date	2026-03-12
Position In Range	0
Ppne	28,047,426
Price Date	2026-05-08
Price EBITDA	EUR 7.97
Ptbv Ratio	1.96
Relative Volume	0.09x
Revenue	251,894,026x
Tax By Revenue	2.04x
Tax Rate	23.5%
Tr20y	112.37%
Tr6m	-1.78%
Volume	270
Z Score	4.32

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

BME/PRM dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+3.6%

$0.47 annual per share

Payout ratio

+47.9%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+8.2%

2 consecutive years of growth

Total shareholder yield

+3.5%

Next ex-dividend date: 2026-03-10

Performance

BME/PRM stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BME/PRM?

Insider, institutional, and short-interest positioning.

Institutional ownership

+12.8%

Share of float held by funds and institutions

Insider ownership

n/a

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.0%

Negative means the company is buying back shares.

Technical

BME/PRM momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

52.8

Neutral momentum band

Price vs 200-day MA

-0.4%

50/200-day relationship not available

Beta (5Y)

0.52

Less volatile than the market

Sharpe ratio

0.78

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BME/PRM

Hub-level FAQ points readers to the deeper analysis pages.

What is the current bme/PRM stock rating?

bme/PRM is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full bme/PRM analysis?

The full report lives at /stocks/bme/PRM/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for bme/PRM?

The latest report frames bme/PRM around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the bme/PRM page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.